AI Can Design Antibodies Faster Than Anyone Can Check Them for Immune Risk. That Gap Is Starting to Close.
Key Highlights
- ➤MindWalk screened 890,634 antibody sequences in 4 hours, 41 minutes using AMD-powered instances
- ➤AMD Q2 2026 revenue $11.5 billion, Data Center revenue $6.7 billion, up 107% year over year
- ➤NVIDIA Q2 fiscal 2027 revenue $96.2 billion, up 106%; Data Center revenue $89.0 billion
- ➤Absci reported positive interim Phase 1 data for ABS-201, with half-life estimated at least 65 days
- ➤AbCellera’s ABCL635 cut moderate-to-severe symptoms by 8.8 daily events versus 3.5 for placebo
Expert Statements
Jennifer Bath, President and Chief Executive Officer of MindWalk
“Every antibody drug carries a question: will the patient’s own immune system attack it”
Jennifer Bath, President and Chief Executive Officer of MindWalk
“Answering that question late is one of the most expensive failures in this industry. Answering it early has been impractical, because AI has been designing possible candidates far faster than anyone could screen them.”
Dirk Van Hyfte, MD, PhD, Chief Technology Officer of MindWalk
“Our work with AMD now spans their accelerators and server CPUs”
Dirk Van Hyfte, MD, PhD, Chief Technology Officer of MindWalk
“That gives us a compute foundation that can scale with the complexity and volume of modern drug discovery.”
Lisa Su, Chair and CEO of AMD
“We enter the second half with strong momentum as EPYC demand accelerates, Instinct deployments scale and Helios begins to ramp”
Jensen Huang, Founder and CEO of NVIDIA
“Frontier models are the brains. BioNeMo is the scientific toolbox.”
Jensen Huang, Founder and CEO of NVIDIA
“Together, they give AI agents the skills of a PhD research assistant and the speed of a supercomputer.”
Sean McClain, Founder and CEO of Absci
“We are fast approaching defining moments for Absci, with interim proof-of-concept data for pattern hair loss later this year and our full 26-week readout in early 2027”
Sarah Noonberg, M.D., Ph.D., Chief Medical Officer of AbCellera
“These positive results represent a significant milestone for women’s health and for AbCellera”
AUSTIN, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Wall Street Investor News Commentary - Antibodies have become one of medicine’s most valuable drug classes, with 144 FDA-approved antibody drugs on the market as of August 2025 and global sales of more than $267 billion in 2024, according to a review published in the Journal of Biomedical Science. Artificial intelligence is now generating antibody candidates by the thousands. The harder question is whether the patient’s immune system will accept them, and checking that early, across every candidate, has been too slow and too expensive to do routinely. That is changing as the software that screens for immune risk and the processors that run it catch up with the pace of AI design. Companies mentioned in today’s commentary include: MindWalk Holdings Corp. (NASDAQ: HYFT), Advanced Micro Devices, Inc. (NASDAQ: AMD), NVIDIA Corporation (NASDAQ: NVDA), Absci Corporation (NASDAQ: ABSI), AbCellera Biologics Inc. (NASDAQ: ABCL).
Get started
Create a free account to read the full story.